Invitae Accelerates Personalized Oncology Testing With Genosity Acquisition

Published Apr 05 2021 at 1:29 PM GMT
  • Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests.
  • Deal consideration of approximately $200 million includes roughly $120 million in cash and roughly $80 million in Invitae common stock.
  • Invitae is currently developing its Personalized Cancer.


  • Published Apr 5, 2021 1:29 PM GMT